Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheng-Ta Yang

Showing results (191-200 of 310) with videos related to

Pageof 31
Sort By:
Future Oncology (London, England)|October 20, 2018
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational studyMaximilian J Hochmair, Alessandro Morabito, Desiree Hao, et al.
Cancers|October 27, 2022
Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer PatientsYan-Jei Tang, John Wen-Cheng Chang, Ching-Fu Chang, et al.
Lung Cancer (Amsterdam, Netherlands)|October 28, 2025
Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world studyMyung-Ju Ahn, Steven H Lin, Cheng-Ta Yang, et al.
JMIR Public Health and Surveillance|April 4, 2022
Papers Please - Predictive Factors of National and International Attitudes Toward Immunity and Vaccination Passports: Online Representative SurveysPaul M Garrett, Joshua P White, Simon Dennis, et al.
Thoracic Cancer|August 1, 2023
Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR-mutated NSCLC treated with afatinibChen-Te Wu, Ping-Chih Hsu, John Wen-Cheng Chang, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine|March 27, 2020
Severe OSA associated with higher risk of mortality in stage III and IV lung cancerHung-Yu Huang, Shih-Wei Lin, Li-Pang Chuang, et al.
JTO Clinical and Research Reports|March 7, 2022
An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE StudyPo-Lan Su, Gee-Chen Chang, Shih-Hsin Hsiao, et al.
Respiratory Care|December 14, 2011
High-frequency oscillatory ventilation for rescue from refractory hypoxemia in a patient with transfusion-related acute lung injuryChin-Hua Huang, Han-Chung Hu, Meng-Jer Hsieh, et al.
Biochemical and Biophysical Research Communications|January 24, 2006
Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell linesYu-Ching Lin, Liang You, Zhidong Xu, et al.
Targeted Oncology|July 27, 2019
Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of OsimertinibChih-Hsi Scott Kuo, Chi-Hsien Huang, Chien-Ying Liu, et al.
Pageof 31

Showing results (191-200 of 310) with videos related to

Sort By:
Pageof 31
Future Oncology (London, England)|October 20, 2018
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational studyMaximilian J Hochmair, Alessandro Morabito, Desiree Hao, et al.
Cancers|October 27, 2022
Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer PatientsYan-Jei Tang, John Wen-Cheng Chang, Ching-Fu Chang, et al.
Lung Cancer (Amsterdam, Netherlands)|October 28, 2025
Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world studyMyung-Ju Ahn, Steven H Lin, Cheng-Ta Yang, et al.
JMIR Public Health and Surveillance|April 4, 2022
Papers Please - Predictive Factors of National and International Attitudes Toward Immunity and Vaccination Passports: Online Representative SurveysPaul M Garrett, Joshua P White, Simon Dennis, et al.
Thoracic Cancer|August 1, 2023
Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR-mutated NSCLC treated with afatinibChen-Te Wu, Ping-Chih Hsu, John Wen-Cheng Chang, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine|March 27, 2020
Severe OSA associated with higher risk of mortality in stage III and IV lung cancerHung-Yu Huang, Shih-Wei Lin, Li-Pang Chuang, et al.
JTO Clinical and Research Reports|March 7, 2022
An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE StudyPo-Lan Su, Gee-Chen Chang, Shih-Hsin Hsiao, et al.
Respiratory Care|December 14, 2011
High-frequency oscillatory ventilation for rescue from refractory hypoxemia in a patient with transfusion-related acute lung injuryChin-Hua Huang, Han-Chung Hu, Meng-Jer Hsieh, et al.
Biochemical and Biophysical Research Communications|January 24, 2006
Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell linesYu-Ching Lin, Liang You, Zhidong Xu, et al.
Targeted Oncology|July 27, 2019
Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of OsimertinibChih-Hsi Scott Kuo, Chi-Hsien Huang, Chien-Ying Liu, et al.
Pageof 31